Long-term follow-up of ruxolitinib in the treatment of steroid-refractory chronic graft-versus-host disease (GVHD)

Chronic graft-versus-host disease (cGVHD) remains a major barrier to a successful hematopoietic stem cell transplantation (HSCT); in cases refractory to first-line therapy with steroids, there is no standard of care for second-line therapy. As such, ruxolitinib is a promising drug in this scenario. We retrospectively analyzed its efficacy and safety as treatment of steroid-refractory cGVHD in 35 patients from two transplant centers, with the longest follow-up described to date. Evaluated patients had a median of 3 organs affected (1-7), with most (64%) having moderate cGVHD.

Source: Biology of Blood and Marrow Transplantation - June 8, 2021 Category: Hematology Authors: Aliana Meneses Ferreira, Roberta Shcolnik Szor, Vinicius Campos Molla, Maria Cristina Seiwald, Pedro Arruda de Moraes, Ana Rita Brito Medeiros da Fonseca, Erick Menezes Xavier, Mariana Gomes Serpa, Luciana Tucunduva, Yana Novis, Celso Arrais-Rodrigues Source Type: research